This paper presents a case of fatal overdosage due to an accidental massive administration (750 mg instead of 170 rag) of cisplatin, an anticancer agent, to a 63.year-old patient suffering from lymphoma. Platinum was measured in various postmortem samples by means of inductively coupled plasma mass spectrometry. Heart and peripheral blood concentrations of platinum were 1515 and 1253 pg/t, respectively. Concentrations in urine and bile were 1038 and 501 pg/L, respectively. Renal dialysis was started immediately after the end of cisplatin perfusion, when the mistake was noticed, but the patient deceased at day 16, presenting renal and hepatic insufficiency, ototoxicity, and pancytopenia.
Introduction
Cisplatin ( Figure 1 ) is a widely used anticancer agent (Platinol | administered in combination chemotherapy against a variety of tumors: colorectal cancer, uterine cancer, small-cell lung carcinoma, or recurrent lymphoma (1) . Nausea, vomiting, and diarrhea are the most common nonhematologic toxic properties of the drug. Neutropenia, lymphocytopenia, and thrombocytopenia are observed in 15-30% of the treated subjects. Nephrotoxicity and ototoxicity seem clearly related to plasma concentration of platinum 12 or 24 h after the end of the perfusion (2), even if pharmacokinetic data depends on the way 9 Author to whom correspondence should be addressed: Dr. Corinne Charlier, Laboraloire de Toxicologie Clinique, Tour II, 5~'me ~'tage, CHU du Sart-Tilman, B-4000 Liege, Belgique. E-mail: C.CHARLIER@chu.ulg.ac.be.
cisplatin is administered (3) and on the renal function of the patient. After cisplatin infusion, platinum accumulates in different organs, and peak platinum levels (reached after 90-150 rain) decline in a triphasic manner in all blood compartments (Ty, u: 13 min, Tr~ [3:43 min, and Ty, 5:7776 min) (2, 4) . The clearance and volume of distribution for all platinum species are significantly related to body surface area of the patient (5). Usual doses are 60-140 mg/m 2, with intravenous constant infusion for 90 rain for 3-5 consecutive days every 3 weeks (5,6), but the optimal administration schedule of cisplatin is still controversial (1) . Cisplatin can be pharmacokinetically monitored by measurement of parent compound in blood (therapeutic range 1000-5000 IJg/L)(7) or by platinum determination in whole blood, plasma, or plasma ultrafiltrate. Platinum concentrations in whole blood are highly related to administration schedule and body surface area but should not be higher than 5000 IJg/L because toxicity can occur even at therapeutic level (2, 7) . Free platinum can be detected in blood at low levels for up to three months after last administration, and platinum quantitation before a new administration is recommended to avoid a cumulative toxicity (2) . If platinum quantitation is not available, hematological formula has to be controlled. Moreover, the residual nephrotoxicity after the last cisplatin treatment can be appreciated by serum creatinine and creatinine clearance determinations (8) .
Case History
This paper presents a case of fatality due to the accidental administration of 750 mg cisplatin instead of 170 mg to a 63-yearold male treated for a recurrent lymphoma. The patient was hospitalized for the third course of cisplatin therapy when the error occurred. Immediately after perfusion, the mistake was noticed and the patient was transferred in the nephrology department for dialysis. After a first extra-renal dialysis cycle, the patient was admitted to the intensive care unit for repeated renal dialysis. At admission, his Glasgow score was 15, and hemodynamic parameters were normal. N-Acetylcystein was administered as adjuvant therapy. On day 2, serum creatinine was increased and patient complained of ototoxicity. On day 3, severe alteration of visual field was noticed, and the patient be-came completely deaf and finally blind at day 6. Hepatic cytolysis was moderate, but a severe hematotoxicity appeared at day 5 with thrombopenia (< 20,000/IJL) and neutropenia (< 2000/IJL). Due to anemia, globule transfusion and erythropo'fetin administration were started at day 5. Despite repeated plasmapheresis, the patient developed septicemia at day 8. Antiobiotherapy was immediately started and was successful. An important polypnea appeared and the patient was intubated at day 10. Coma occurred at day 11, and only sedative treatments were continued. The patient deceased at day 16. Autopsy findings were unremarkable. Cardiac and femoral blood, urine, and bile were sampled for toxicological investigations.
Toxicological Analysis
Antemortem determinations of cisplatin in blood were carried out by high-performance liquid chromatography (HPLC) (9) and are presented in Table I . After perfusion and just before renal dialysis, the cisplatin concentration exceeded the highest therapeutic level by approximately 2 times. Autopsy samples were analyzed for general unknown using head-space gas chromatography (GC), GC-mass spectrometry (MS), and liquid chromatography-diode array detection (LC-DAD), with a special focus for alcohol, benzodiazepines, carboxyhemoglobinemia, and opiates. Alcohol was undetectable in both blood and urine, and carboxyhemoglobinemia was strictly normal. Midazolam was identified in postmortem blood by LC-DAD and quantitated at 563 ng/mL, which is higher than the therapeutic concentration but compatible with emergency doses. Morphine was detectable in blood (free morphine: 288 ng/mL) and in urine (total morphine: 351 ng/mL). Despite higher than therapeutic concentrations, these levels are in agreement with the palliative treatment started at day 11. Platinum was quantitated in autopsy samples by inductively coupled plasma-MS (ICP-MS) on an Agilent 7500a (Palo Alto, CA) apparatus. The ICP conditions are Table II . Sample preparation consisted of 20-fold dilution of 500 IaL whole blood with nitric acid (0.5%), n-butanol (0.2%), and triton (0.1%) in ultrapure water. Rhodium was used as internal standard (Sigma R8134, Bornem, Belgium). All reagents were of analytical grade. The five-point standard curve of calibration showed a good linearity (r = 0.9994) over the concentration range tested (10-5000 IJg/L). The limit of quantitation (10 times the background noise at m/z 195) was 101Jg/L. Withinrun accuracy and precision, measured at 1000 pg/L (10 replicates), were 8.9 • 1.6% and 6.5 • 2.3%, respectively.
Results and Discussion
Usually, platinum concentrations in plasma have to be monitored after cisplatin therapy, before a new drug administration, in order to prevent nephrotoxicity and accumulation of platinum in tissues. It has been previously reported that plasma platinum concentration decreased to below the detection limit three months after the final dose (10), which is correlated with the cumulative toxicity of the drug. ICP-MS technique was validated to quantitate platinum in various samples and provides a good sensitivity and an excellent specificity together with the ease of sample preparation.
To our knowledge, this case report represents the first accidental fatal outcome by cisplatin poisoning ever published. Resuits are presented in Table III . The platinum concentrations reported here are in agreement with the case history, and analytical results only confirm the clinical conclusions. Nephrotoxicity of cisplatin is known to be associated with platinum concentration in blood 12 or 24 h after the end of the perfusion (2, 11) . Even if the reported platinum concentrations are included in the therapeutic range, it is clear that these values are postmortem results and that two weeks had occurred since the last cisplatin perfusion. Antemortem cisplatin measurements found in this case were associated with acute drug poisoning, and clinical events observed in this case are clearly related to the massive administration of cisplatin. Ototoxicity and visual alterations both occurred during the first 48 h. Renal insufficiency, with elevation of serum creatinine, was observed in the same time and was not corrected by renal dialysis. Hematotoxicity appeared later, concerning all the blood cells. Only hepatic necrosis was moderate; this is in agreement with the reported observation (3) that intravenous administration of cisplatin did not result in high accumulations of platinum in the liver. Quantitation of platinum in the liver of the patient after death should have been interesting to confirm this hypothesis. The postmortem findings and case history are consistent with the death of this man due to cisplatin toxicity. Renal failure occurred despite repeated renal dialysis, and hematotoxicity was severe. Plasmapheresis appeared to be without clinical benefit, despite other existing reports concerning accidental cisplatin overdose corrected by plasmapheresis (12,13), followed by intranenous hydration and sometimes kidney transplant (13) . The poor efficacy of therapeutic means can be related to the poor condition of the patient; it is possible that the cancer disease of the patient also played a role in his death. Moreover, granulocyte-macrophage colony stimulating factors were used to ameliorate myelosuppression in other massive cisplatin overdoses (12,13) but were not in the present reported case. Finally, the fact that the patient was treated with cisplatin for more than one year may have contributed to accumulation of platinum in tissues, with a significant release of the drug in blood caused by cellular necrosis at the time of overdose. This can explain the poor apparent efficacy of renal dialysis and plasmapheresis.
The medical cause of death was attributed to acute cisplatin toxicity, and the manner of death was accidental.
